479: Putting Patients First in Developing Drugs to Transform Radiation Therapy for Cancer - Dr. Robert A. Beardsley

Dr. Robert A. Beardsley or "Al" is a Co-Founder and the Chief Operating Officer at Galera Therapeutics, a clinical-stage biotech company discovering and developing innovative cancer treatments. Al is interested in developing new drugs that target how oxygen is metabolized in cells. In particular, Al and the team at Galera Therapeutics are working to develop therapeutics to use with radiation therapy that will block the processes that cause damage to normal tissue while also increasing damage to the tumor. While Al is passionate about science and drug development, he also enjoys watching soccer, coaching soccer, being outdoors, and hiking in the mountains in his free time. Al received his BS in Chemical Engineering from the University of Iowa, an MBA in finance from the University of Chicago, and subsequently his PhD in Biochemical Engineering from the University of Iowa. Prior to co-founding Galera Therapeutics, Al served as CEO at Metabolic Solutions Development Corporation, CEO of Kereos, acting CEO at Metaphore Pharmaceuticals, and he has held various roles at Confluence Life Sciences, SImile Investors, bioStrategies Group, and Vector Securities International. Galera Therapeutics’ new drug Abasopasem Manganese has been designated as a “Breakthrough Therapy” by the FDA for reduction in the duration, incidence, and severity of oral mucositis induced by radiation therapy in cancer patients. Recently, Al and the team at Galera Therapeutics raised $150 million in investment for their company, which represents the largest single capital round ever raised by a life-sciences company founded in St. Louis. In this podcast interview, Al spoke with us about his experiences in life and science.